Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Dow
Moodys
Colorcon
Johnson and Johnson
Mallinckrodt
Merck

Last Updated: October 20, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Nitrendipine

See Plans and Pricing

« Back to Dashboard

Development status for investigational drug Nitrendipine: Sponsors, patents, clinical trial progress

Nitrendipine is an investigational drug.

There have been 6 clinical trials for Nitrendipine. The most recent clinical trial was a Phase 3 trial, which was initiated on November 1st 2009.

The most common disease conditions in clinical trials are Hypertension, Renal Insufficiency, Chronic, and Kidney Diseases. The leading clinical trial sponsors are Merck KGaA, University of Erlangen-Nürnberg Medical School, and Daiichi Sankyo Europe, GmbH.

There are two US patents protecting this investigational drug and eighteen international patents.

Recent Clinical Trials for Nitrendipine
TitleSponsorPhase
Clinical Studies by Using Accelerated PDX Model to Screen Drugs for Advanced Solid TumorHaining Health-Coming Biotech Co., Ltd.Phase 2
Treatment of Hypertension in Tibetan Adult PopulationWest China HospitalPhase 4
Sympathetic Nerve Activity in Renal FailureUniversity of Erlangen-Nürnberg Medical SchoolPhase 4

See all Nitrendipine clinical trials

Clinical Trial Summary for Nitrendipine

Top disease conditions for Nitrendipine
Top clinical trial sponsors for Nitrendipine

See all Nitrendipine clinical trials

US Patents for Nitrendipine

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Nitrendipine   Start Trial Methods and compositions for treating infection UNIVERSITY OF ROCHESTER (Rochester, NY) UNIVERSITY OF KANSAS (Lawrence, KS)   Start Trial
Nitrendipine   Start Trial Therapeutic approaches for treating Parkinson's disease Pharnext (Issy les Moulineaux, FR)   Start Trial
Nitrendipine   Start Trial Combination therapy Boehringer Ingelheim International GmbH (Ingelheim am Rhein, DE)   Start Trial
Nitrendipine   Start Trial Neprilysin inhibitors THERAVANCE BIOPHARMA R&D IP, LLC (South San Francisco, CA)   Start Trial
Nitrendipine   Start Trial Synthetic linear apelin mimetics for the treatment of heart failure NOVARTIS AG (Basel, CH)   Start Trial
Nitrendipine   Start Trial Combining electronic monitoring with inhaled pharmacological therapy to manage cardiac arrhythmias including atrial fibrillation INCARDA THERAPEUTICS, INC. (Newark, CA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Nitrendipine

Drugname Country Document Number Estimated Expiration Related US Patent
Nitrendipine World Intellectual Property Organization (WIPO) 2014052836 2032-09-27   Start Trial
Nitrendipine Australia 2012222348 2031-03-01   Start Trial
Nitrendipine Australia 2012222351 2031-03-01   Start Trial
Nitrendipine Australia 2013224959 2031-03-01   Start Trial
Nitrendipine Australia 2013224960 2031-03-01   Start Trial
Nitrendipine Australia 2014314055 2031-03-01   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Medtronic
Johnson and Johnson
Baxter
McKesson
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.